Segment Reporting (Tables)

12 Months Ended

Jan. 31, 2023

Segment Reporting [Abstract]

Schedule of net sales and property and equipment

	January 31,
	2023		2022
Net sales
Pocono Pharmaceuticals	$	1,785,597	$	1,179,620
4P Therapeutics		294,102		242,534
		2,079,699		1,422,154
Gross profit
Pocono Pharmaceuticals		726,702		595,087
4P Therapeutics		23,702		(40,777	)
		750,404		554,310
Operating expenses
Selling, general and administrative-Pocono Pharmaceuticals		577,930		556,204
Selling, general and administrative-4P Therapeutics		103,181		96,079
Corporate overhead		3,234,930		3,370,541
Research and development-4P Therapeutics		982,227		411,383
Goodwill impairment-Pocono Pharmaceuticals		327,326		2,180,836
		5,225,594		6,615,043
Depreciation and Amortization
Pocono Pharmaceuticals	$	264,156	$	220,524
4P Therapeutics		65,987		88,217
	$	330,143	$	308,741

Schedule of net sales and property and equipment

	Year Ended
	January 31,
	2023		2022
Net sales:
United States	$	2,079,699	$	1,335,554
Outside the United States		-		86,600
	$	2,079,699	$	1,422,154
Property and equipment, net of accumulated depreciation
United States	$	897,735	$	979,297
Outside the United States		-		-
	$	897,735	$	979,297
Assets:
Corporate	$	1,745,731	$	4,750,937
Pocono Pharmaceuticals		5,400,814		5,639,178
4P Therapeutics		2,309,832		2,349,548
	$	9,456,377	$	12,739,660